Define this disease.
intestinal metaplasia of the esophageal mucosa induced by chronic reflux.
Histopathological examination of the mucosa shows a columnar epithelium instead of the normal squamous epithelium.
A premalignant change that requires close surveillance.
List risk factors for Barret esophagus.
Male sex
European descent
Age ≥ 50 years
Obesity
Symptoms ≥ 5 years
Describe the pathophysiology.
Reflux esophagitis → stomach acid damages mucosa of distal esophagus → nonkeratinized stratified squamous epithelium is replaced by nonciliated columnar epithelium and goblet cells (intestinal metaplasia, Barrett metaplasia)
The physiological transformation zone (Z line) between squamous and columnar epithelium is shifted upwards.
Describe the pathology.
Short-segment (< 3 cm of columnar epithelium between Z line and GEJ)
Long-segment (> 3 cm of columnar epithelium between Z line and GEJ): higher cancer risk
What is the main complication?
esophageal adenocarcinoma
Describe the management and surveillance.
PPI therapy
Consider if asymptomatic.
Continue maintenance therapy long-term if symptomatic.
Endoscopy with four-quadrant biopsies at every 2 cm of the suspicious area (salmon-colored mucosa)
If no dysplasia: Repeat endoscopy every 3–5 years.
If indefinite for dysplasia: Repeat endoscopy with biopsies after 3–6 months of optimized PPI therapy.
If low-grade dysplasia:
Endoscopic therapy of mucosal irregularities
Alternatively: surveillance every 6-12 months with biopsies every 1 cm
If high-grade dysplasia: endoscopic treatment of mucosal irregularities, e.g., radiofrequency ablation
Consider antireflux surgery or resection of the segment based on a specialist's evaluation.
Last changed2 years ago